Pharma Journalist 8791 posts 0 comments

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe…
Read More...

Teva Pharmaceutical Industries Ltd. provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-specified…
Read More...

FSD Pharma Inc. and Prismic Pharmaceuticals Inc. announced that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD…
Read More...

UroGen Pharma Ltd. announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a…
Read More...

2nd Combination Products Lifecycle Management, Boston, April 23: Increasingly fierce competition amongst pharma/biotechs and R&D costs have made drug and device developers…
Read More...

On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal…
Read More...

Oakrum Pharma, LLC (Oakrum) announced that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. Ltd. (Biophore) to develop and manufacture two prescription generic…
Read More...

Elpiscience BioPharma and Bio-Techne Corporation announced that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the…
Read More...

Eli Lilly and Company and Avidity Biosciences, Inc. announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new…
Read More...